CBD Dramatically Improved Seizures, Sleep, and Language in a Rare Genetic Epilepsy Case
A 30-year-old woman with a rare genetic developmental epileptic encephalopathy experienced major improvements in seizures, sleep, mood, language, and motor skills after starting CBD.
Quick Facts
What This Study Found
Off-label cannabidiol produced significant seizure frequency reduction in a patient with a rare genetic DEE not covered by current CBD indications. Beyond seizure control, the patient showed striking improvements in sleep quality, mood, behavior, language, and motor skills.
Key Numbers
One 30-year-old patient. Relevant seizure frequency reduction. Improvements noted in sleep quality, mood, behavior, language, and motor skills.
How They Did This
Single case report of a 30-year-old female with a rare genetic developmental epileptic encephalopathy treated with off-label cannabidiol after drug-resistant seizures failed to respond to standard therapies.
Why This Research Matters
CBD is currently approved only for three specific epilepsy conditions. This case suggests potential benefit in other genetic epilepsies and highlights effects beyond seizure reduction.
The Bigger Picture
Developmental epileptic encephalopathies beyond the three approved indications are a significant unmet medical need. If CBD benefits extend to other genetic DEEs, the approved indication list may need to expand.
What This Study Doesn't Tell Us
Single case report cannot establish efficacy. Placebo effect and natural disease fluctuation cannot be ruled out.
Questions This Raises
- ?Should clinical trials of CBD be expanded to include other genetic developmental epileptic encephalopathies?
- ?What mechanism explains CBD's broad improvements beyond seizure reduction?
Trust & Context
- Key Stat:
- Beyond seizure reduction, CBD improved sleep, mood, language, and motor skills in a rare genetic epilepsy
- Evidence Grade:
- Single case report provides the lowest level of clinical evidence, though the breadth of improvement is notable.
- Study Age:
- Published in 2024.
- Original Title:
- Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report.
- Published In:
- Epilepsy & behavior reports, 27, 100687 (2024)
- Authors:
- Mannini, Elisa, Misirocchi, Francesco, Lazzari, Stefania, Balella, Giulia, Bottignole, Dario, Frapporti, Maddalena, Zinno, Lucia, Florindo, Irene, Parrino, Liborio, Mutti, Carlotta
- Database ID:
- RTHC-05510
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
Is CBD only approved for specific types of epilepsy?
Yes, currently for Lennox-Gastaut, Dravet syndrome, and tuberous sclerosis complex. This case shows potential benefit in other genetic epilepsies.
Can CBD help with more than just seizures?
In this case, the patient also experienced improvements in sleep, mood, behavior, language, and motor skills.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05510APA
Mannini, Elisa; Misirocchi, Francesco; Lazzari, Stefania; Balella, Giulia; Bottignole, Dario; Frapporti, Maddalena; Zinno, Lucia; Florindo, Irene; Parrino, Liborio; Mutti, Carlotta. (2024). Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report.. Epilepsy & behavior reports, 27, 100687. https://doi.org/10.1016/j.ebr.2024.100687
MLA
Mannini, Elisa, et al. "Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report.." Epilepsy & behavior reports, 2024. https://doi.org/10.1016/j.ebr.2024.100687
RethinkTHC
RethinkTHC Research Database. "Off-label use of cannabidiol in genetic epileptic and develo..." RTHC-05510. Retrieved from https://rethinkthc.com/research/mannini-2024-offlabel-use-of-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.